🟢 Moleculin Biotech is trading 10% up today after 37% blinded composite complete remission data

Moleculin Biotech is trading 10% up now at $0.45 after positive blinded MIRACLE AML data continued attracting investor attention.

• The company has not identified a new August 10 announcement.
• July 31 interim data showed a 37% blinded composite complete remission rate.
• The recently completed $9.3 million offering may support Annamycin development but introduces dilution considerations.